BBD-017

COMPARISON OF THE IMPACT OF THREE ONE-SHOT VACCINES AGAINST *MYCOPLASMA HYOPNEUMONIAE* ON PRODUCTIVE PARAMETERS IN A FIELD TRIAL

D. Espigares [1], P. Del Carmen [2], M. Lasierra [2], S. Cárceles [2], M. Carmona [2].

[1] Ceva Salud Animal, Roldán, Spain; [2] Ceva Salud Animal, Barcelona, Spain.

Introduction

Vaccination against *Mycoplasma hyopneumoniae* has become an efficient tool to control and reduce economic losses associated with Enzootic Pneumonia (EP). The aim of this field trial was to compare the effect on productive parameters of three commercial one-shot vaccines against *M. hyopneumoniae(Mh)*.

Material and methods

The field trial was performed in 2016 in a 5.000 sows farm and 55.600 animals of 27 batches were included. Productive parameters and lung lesion scores were collected from 14 batches vaccinated with Hyogen® Ceva, 9 batches vaccinated with Vaccine B(Mh) and 4 batches with Vaccine C(PCV2+Mh RTU). The economic balance in the 3 groups was calculated using Respinomics®app.

Results

The performance was as follows: batches vaccinated with Hyogen® had FCR 2,293 points and ADG 668 gr.; batches vaccinated with vaccine B had FCR 2,406 and ADG 631 gr.; and batches vaccinated with vaccine C had FCR 2,367 and ADG 627 gr. The differences between the Hyogen® group and groups B and C were statistically different both for FCR and for ADG ($p<0,05$).

Hyogen® group showed the percentage of lungs with Ep-like lesions of 45,21%, and the average affected lung surface of 3,01%. The percentage of lungs with EP-like lesions in group B was 48,55%, and the affected surface 4,21%. In group C the% of lungs with EP-like lesions was 53,21% and the affected surface 5,67%.

The economic analysis of the three groups showed a higher net profit in the Hyogen® group of 1,65€ and 2,48 €/animal compared with Vaccine B and Vaccine C groups respectively.

Conclusion

In this field trial, Hyogen® demonstrated to be the best option to improve FCR and ADG, and consequently to increase the profit compared to two mostly used Mhyo vaccines. Thus, vaccination with Hyogen® could contribute better than those vaccines to reduce the economic impact of enzootic pneumonia.